These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 30818855)
1. Liposomal Irinotecan for Treatment of Colorectal Cancer in a Preclinical Model. Huang JR; Lee MH; Li WS; Wu HC Cancers (Basel); 2019 Feb; 11(3):. PubMed ID: 30818855 [TBL] [Abstract][Full Text] [Related]
2. Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer. Leonard SC; Lee H; Gaddy DF; Klinz SG; Paz N; Kalra AV; Drummond DC; Chan DC; Bunn PA; Fitzgerald JB; Hendriks BS Anticancer Drugs; 2017 Nov; 28(10):1086-1096. PubMed ID: 28857767 [TBL] [Abstract][Full Text] [Related]
3. Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy. Awasthi N; Schwarz MA; Zhang C; Klinz SG; Meyer-Losic F; Beaufils B; Thiagalingam A; Schwarz RE Mol Cancer Ther; 2022 Jul; 21(7):1149-1159. PubMed ID: 35500018 [TBL] [Abstract][Full Text] [Related]
4. [Molecular mechanism of resveratrol combined with irinotecan in treatment of colorectal cancer]. Li F; Yan RY; Li KY; Wang J; Wang L; Shen H; Han CL; Liu M Zhongguo Zhong Yao Za Zhi; 2023 Apr; 48(8):2212-2221. PubMed ID: 37282909 [TBL] [Abstract][Full Text] [Related]
5. Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer. Messerer CL; Ramsay EC; Waterhouse D; Ng R; Simms EM; Harasym N; Tardi P; Mayer LD; Bally MB Clin Cancer Res; 2004 Oct; 10(19):6638-49. PubMed ID: 15475454 [TBL] [Abstract][Full Text] [Related]
6. Focused ultrasound and interleukin-4 receptor-targeted liposomal doxorubicin for enhanced targeted drug delivery and antitumor effect in glioblastoma multiforme. Yang FY; Wong TT; Teng MC; Liu RS; Lu M; Liang HF; Wei MC J Control Release; 2012 Jun; 160(3):652-8. PubMed ID: 22405901 [TBL] [Abstract][Full Text] [Related]
7. EGFR-targeted multifunctional polymersomal doxorubicin induces selective and potent suppression of orthotopic human liver cancer in vivo. Fang Y; Yang W; Cheng L; Meng F; Zhang J; Zhong Z Acta Biomater; 2017 Dec; 64():323-333. PubMed ID: 29030307 [TBL] [Abstract][Full Text] [Related]
8. Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression. Kang MH; Wang J; Makena MR; Lee JS; Paz N; Hall CP; Song MM; Calderon RI; Cruz RE; Hindle A; Ko W; Fitzgerald JB; Drummond DC; Triche TJ; Reynolds CP Clin Cancer Res; 2015 Mar; 21(5):1139-50. PubMed ID: 25733708 [TBL] [Abstract][Full Text] [Related]
9. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion. Kalra AV; Kim J; Klinz SG; Paz N; Cain J; Drummond DC; Nielsen UB; Fitzgerald JB Cancer Res; 2014 Dec; 74(23):7003-13. PubMed ID: 25273092 [TBL] [Abstract][Full Text] [Related]
10. Liposomal Irinotecan Achieves Significant Survival and Tumor Burden Control in a Triple Negative Breast Cancer Model of Spontaneous Metastasis. Bernards N; Ventura M; Fricke IB; Hendriks BS; Fitzgerald J; Lee H; Zheng J Mol Pharm; 2018 Sep; 15(9):4132-4138. PubMed ID: 30059232 [TBL] [Abstract][Full Text] [Related]
11. Irinotecan Upregulates Fibroblast Growth Factor Receptor 3 Expression in Colorectal Cancer Cells, Which Mitigates Irinotecan-Induced Apoptosis. Erdem ZN; Schwarz S; Drev D; Heinzle C; Reti A; Heffeter P; Hudec X; Holzmann K; Grasl-Kraupp B; Berger W; Grusch M; Marian B Transl Oncol; 2017 Jun; 10(3):332-339. PubMed ID: 28340475 [TBL] [Abstract][Full Text] [Related]
12. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. Wang-Gillam A; Hubner RA; Siveke JT; Von Hoff DD; Belanger B; de Jong FA; Mirakhur B; Chen LT Eur J Cancer; 2019 Feb; 108():78-87. PubMed ID: 30654298 [TBL] [Abstract][Full Text] [Related]
13. GE11-Directed Functional Polymersomal Doxorubicin as an Advanced Alternative to Clinical Liposomal Formulation for Ovarian Cancer Treatment. Zou Y; Xia Y; Meng F; Zhang J; Zhong Z Mol Pharm; 2018 Sep; 15(9):3664-3671. PubMed ID: 29570299 [TBL] [Abstract][Full Text] [Related]
14. Multiple sessions of liposomal doxorubicin delivery via focused ultrasound mediated blood-brain barrier disruption: a safety study. Aryal M; Vykhodtseva N; Zhang YZ; McDannold N J Control Release; 2015 Apr; 204():60-9. PubMed ID: 25724272 [TBL] [Abstract][Full Text] [Related]
15. Enhanced uptake and improved anti-tumor efficacy of doxorubicin loaded fibrin gel with liposomal apatinib in colorectal cancer. Hu Y; Wu C; Zhu C; Fu Q; Guo J; Deng L; He Y; Yang D; Cheng Y; Gao X Int J Pharm; 2018 Dec; 552(1-2):319-327. PubMed ID: 30308269 [TBL] [Abstract][Full Text] [Related]
16. Low-toxicity transferrin-guided polymersomal doxorubicin for potent chemotherapy of orthotopic hepatocellular carcinoma in vivo. Wei Y; Gu X; Cheng L; Meng F; Storm G; Zhong Z Acta Biomater; 2019 Jul; 92():196-204. PubMed ID: 31102765 [TBL] [Abstract][Full Text] [Related]
17. Comparison of the therapeutic efficacy of 188Rhenium-liposomes and liposomal doxorubicin in a 4T1 murine orthotopic breast cancer model. Liu CM; Lee WC; Yu CY; Lan KL; Chang CH; Ting G; Lee TW Oncol Rep; 2012 Mar; 27(3):678-84. PubMed ID: 22109644 [TBL] [Abstract][Full Text] [Related]
18. Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. Kalofonos HP; Aravantinos G; Kosmidis P; Papakostas P; Economopoulos T; Dimopoulos M; Skarlos D; Bamias A; Pectasides D; Chalkidou S; Karina M; Koutras A; Samantas E; Bacoyiannis C; Samelis GF; Basdanis G; Kalfarentzos F; Fountzilas G Ann Oncol; 2005 Jun; 16(6):869-77. PubMed ID: 15855226 [TBL] [Abstract][Full Text] [Related]
19. cRGD-decorated biodegradable polytyrosine nanoparticles for robust encapsulation and targeted delivery of doxorubicin to colorectal cancer in vivo. Gu X; Wei Y; Fan Q; Sun H; Cheng R; Zhong Z; Deng C J Control Release; 2019 May; 301():110-118. PubMed ID: 30898610 [TBL] [Abstract][Full Text] [Related]
20. Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience. Tossey JC; Reardon J; VanDeusen JB; Noonan AM; Porter K; Arango MJ Med Oncol; 2019 Sep; 36(10):87. PubMed ID: 31494781 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]